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Quantitative analysis of histo- 
and cytochemical components 
such as DNA, RNA or chromatin 
pattern on one hand (cytometry) 
and the quantitative analysis of 
geometric non-chemical cell and 
tissue components (morphom-
etry and sterology) on the other, 
have developed somewhat inde-
pendently. Today, many different 
techniques, such as morphom-
etry, sterology, and static image 
and ﬂow cytometry are well es-
tablished and routinely used in 
diagnostic quantitative pathology. 
The potential signiﬁcance of these 
techniques in the individualization 
of care in cancer patients include 
the objective distinction between 
benign, borderline and malignant 
lesions, objective grading of inva-
sive tumours, prediction of prog-
nosis, and therapy response.
The ﬁrst description of cell nucle-
us was given by Brown in 1833 
and the ﬁrst microscopic descrip-
tion of human malignant tumours 
by Müller in 1838 (1). Among 
the ﬁrst to apply the microscope 
to the study of human cells was 
the French microscopist Donné, 
whose work culminated in an at-
las published in 1845 (2). In 1870     www.ljm.org.ly   
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in Basel, Miescher isolated nu-
cleic acids from Salmon sperm. 
As early as 1890 (3), David von 
Hansemann postulated all can-
cers are characterised by asym-
metrical cell division that ulti-
mately leads to cancer. Sterobe 
in 1892 (4) found asymmetrical 
mitoses in regenerative tissues 
and non-malignant tumours. 
In 1904, Kohler constructed a 
monochromatic microscope and 
described the absorption of ul-
traviolet light (UV) by the nuclei. 
In the same year, Dhere in Paris 
demonstrated nucleic acids abil-
ity to absorb ultraviolet light. In 
contrast to Hansemann, Boveri’s 
(1914) (5) hypothesis on cancer 
relied on qualititative changes in 
chromosomes of cancer cells. In 
1933 (6), Haumeder proved that 
cancer cells have nuclei larger 
than normal, which suggested a 
higher DNA nuclear content. In 
1924 (7), Feulgen produced the 
chromogenic stoichiometric reac-
tion for DNA, which allowed the 
measurement of nuclear DNA 
content in cells on microscopical 
slides. The work of Caspersson 
and his colleagues in Stockholm 
between 1932 and 1939 marked 
the beginning of modern quanti-
tative cytometry. They combined 
the observations of Kohler and 
Dhere with microscopic meas-
urements and determined the 
amount of DNA in the nuclei. Due 
to the advent of improved elec-
tronic equipment and digital com-
puters in the 1950s and 1960s, 
rapid DNA cell analysis, cell sort-
ing, and quantitative chromatin 
pattern analysis could be applied 
at a much larger scale than be-
fore the Second World War.
As early as 1925, morphometric 
analysis started. Jacobi, in 1925 
(8), found that the volume of a nor-
mal cell doubles before cell divi-
sion. Heiberg and Kemp, in 1929 
(9), were probably the ﬁrst to sub-
stantiate the subjective impres-
sion that cancer nuclei are larger 
than those of normal cells. In the 
1950s and 1960s, an increased 
interest amongst anatomists and 
biologists gave a strong impetus 
to morphological and stereologi-
cal analysis in biomedicine. In the 
late 1970s and early 1980s, the 
application of morphometric anal-
ysis to pathologically changed tis-
sues became increasingly popular 
and widely applied, particularly in 
cancer. Morphometric techniques 
are fairly simple and inexpensive, 
but sometimes time-consuming. 
On the other hand, DNA cytom-
etry is more expensive, but highly 
reproducible.
The sharp increase in interest in 
the application of quantitative pa-Libyan Journal of Medicine, Volume 1, 2006
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thology to cancer diagnosis and 
prognosis is mainly due to the fol-
lowing reasons: (a) the increased 
social demands of quantitation 
and objectivity; (b) the improve-
ment in, and widespread avail-
ability of, adequate technology; 
(c) the awareness that changes 
can be detected with quantita-
tive analysis which would other-
wise escape observation; (d) the 
improvement of therapeutic pos-
sibilities for cancer patients. Fi-
nally, the opinions of pathologists 
have not always proved consist-
ent or reproducible while quanti-
tative pathological analyses are 
more reproducible and capable 
of preventing under- and over 
treatment. For a detailed histori-
cal account the reader is referred 
to (Koss 1982 (10), 1987 (11), 
Caspersson 1987 (12), Baak 
1991 (13), Mariuzzi and Collan 
1995 (14).
DNA cytometry: Cancer devel-
ops through a sequence of cel-
lular events reﬂected by various 
degrees of atypia (Brawer 1992 
(15)), and numerous reports 
have indicated that such events 
are associated with alterations in 
nuclear DNA contents and cellu-
lar morphometric size and shape 
features (Malinin et al. 1988 (16), 
Merkel and McGuire 1990 (17), 
William and Daly 1990 (18). 
Both ﬂow cytometry and static im-
age cytometry analysis have been 
used to determine DNA ploidy of 
cancer. But both of these tech-
niques have some limitations. 
Flow cytometry cannot be per-
formed successfully when only a 
small amount of tumor cells are 
present in the needle biopsy. This 
is because plain ﬂow cytometry 
has practically no ability to dis-
tinguish tumor from non-tumor 
cells. Therefore, a small number 
of non-diploid (aneuploidy) cells 
may be diluted to insigniﬁcance 
by larger numbers of benign dip-
loid cells (19). In contrast, static 
image analysis allows determina-
tion of ploidy in both cytological 
smears and tissue sections with 
relatively small amounts of tumor. 
Unfortunately, the interpretation 
of results is still hampered by the 
lack of standard methodologies 
(20, 21). Simple (22-25) and com-    www.ljm.org.ly   
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plex algorithms (26, 27), and/or 
classiﬁcation strategies (28-30) 
which could make the interpre-
tation of histograms more ob-
jective for diagnosis, prognosti-
cation, and therapy planning of 
the neoplasm were created.
Figure 1: (A) There are no values 
outside the diploid range. Even 
though the number of cells studied 
is low, this type of histogram with-
out any evidence of non-diploidy can 
be considered diploid. (B) Dominant 
tetraploid peak, only a few nuclei out-
side the peritetraploid region (3.4c-
4.4c). There are no diploid nuclei. (C) 
Prominent peak at 3c region with a 
broad peak at 6c that may reﬂect the 
proliferative cells of dominant popu-
lation. (D) Multiple broad aneuploid 
peaks of numerous DNA values are 
seen over the whole range of the his-
togram. (c=haploid DNA content).
On the basis of ﬂow cytometry, 
Tribukait prepared a theory 
on the progression of prostate 
cancer (31, 32). The model is 
a three-compartment model of 
ploidy progression describing 
how a diploid tumor progresses 
to tetraploid tumours and sub-
sequently becomes aneuploid. 
This theory was furnished by 
repetitive ﬂow cytometric study 
of FNAB specimens (33). This 
evidence is much in line with 
that of Auer in breast cancer Libyan Journal of Medicine, Volume 1, 2006
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(34) and also supported by the 
evidence of static image cytom-
etry by Buhmeida and Collan 
(35), but the early phases may 
include near diploid cases more 
often than ﬂow cytometry detects 
them.
DNA studies have shown that pa-
tients with diploid cancers (Figure 
1. A) have longer disease-free 
intervals and survival times than 
those with non-diploid tumors 
(Figure 1. B, C, and D) (36). How-
ever, they may not be so helpful 
in predicting stage for an indi-
vidual patient. The ﬁrst report on 
the relationship of DNA ploidy of 
prostate carcinoma with progno-
sis appeared in 1966 (37).
It has been suggested that cy-
tological smear preparations are 
more suitable than tissue sections 
for determination of DNA content 
and morphometric parameters 
such as nuclear shape, size, and 
texture due to less overlap be-
tween cells and between cell nu-
clei (38). In a multivariate analysis, 
Forsslund et al (39) showed that 
DNA ploidy was a better predictor 
of survival than histological grade 
and tumour stage. Frankfurt and 
his colleagues (40) examined 45 
patients with prostate cancer and 
noted that all 11 patients with or-
gan conﬁned cancer had diploid 
tumors. None of the aneuploid tu-
mors were organ conﬁned.
The most convincing evidence of 
the prognostic role of DNA con-
tent comes from a study by For-
sslund and Zetterberg (41) where 
DNA was measured in a series 
of patients with a long-term fol-
low-up. Patients who died within 
3 years of diagnosis consistent-
ly had DNA stemlines at 3c and 
6c, whereas long-term survivors 
(>15 years) had stemlines at 2c 
and 4c. In the Mayo Clinic prosta-
tectomy series, ploidy was one of 
the signiﬁcant predictive factors 
found in multivariate analysis of 
tumour characteristics (42).
Several clinical and pathological 
variables are useful in assessing 
the prognosis of cancer patients. 
Therefore, an active search is on-
going for powerful new prognos-
tic and predictive tools capable of 
identifying high-risk patients who 
would beneﬁt from individually tai-
lored treatment options (43). As a 
part of this ongoing search, focus 
has been recently made on DNA 
quantiﬁcation, which might pro-
vide useful prognostic informa-
tion (44). Indeed, abnormalities in 
DNA ploidy are seen in many hu-
man tumors, and determination 
of ploidy and proliferative activity 
has been shown to provide prog-    www.ljm.org.ly   
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nostic information in several solid 
tumors (45, 46). While several 
studies have suggested that DNA 
ploidy is an independent prog-
nostic factor (47-49) others have 
reported that DNA content is not 
associated with clinical outcome 
(50,51). Part of these discrepant 
observations might be explained 
by the inconsistencies and true 
differences in the technical as-
pects of recording the DNA con-
tents. Also, it is well known that 
some cancer tumours consist of 
many different subpopulations 
of tumor cells with different DNA 
content (52,53).
To overcome this problem, the 
introduction of some other quan-
titative tools, such as immuno-
histochemical staining, RT PCR, 
and DNA microarray etc., might 
help ﬁnd biological markers that 
combined together to form bio-
logical models that could help in 
knowing more about the biology 
and behavior of cancer.
Aneuploidy is one of the features 
of cancer cells that distinguish 
them from normal cells (54). Be-
cause aneuploidy has been rec-
ognized as a cardinal feature of 
many cancers, it plays an impor-
tant part in tumourigenesis and is 
considered as a potential thera-
peutic target once the causes 
are revealed by further investiga-
tions.
Genomic instability is observed 
in the majority of human tumors. 
Dysregulation of the mitotic spin-
dle checkpoint is thought to be 
one of the mechanisms facilitat-
ing aneuploidy in tumor cells (55). 
However, the mechanisms behind 
genetic instability and aneuploidy 
still remain unexplored (56).
Nuclear Morphometry: Dur-
ing the past several years, it has 
been well established that sev-
eral clinical and histopathological 
variables are helpful in predicting 
the clinical outcome of cancer pa-
tients. Such prognostic predictors 
include tumour stage (57,58), his-
tological type, tumour differentia-
tion, ploidy, proliferative activity, 
p53 expression, apoptosis, and 
vascular and lymphatic invasion. 
Among the most powerful prog-
nostic determinants in colorectal 
cancer, for example, is the his-
tological tumour stage, including 
the depth of local invasion into 
the bowel wall and the inﬁltration 
in the regional lymph nodes (59-
61). Despite this fact, the clini-
cal staging of colorectal cancer 
is currently based on information 
not obtainable by histological ex-
amination of the primary tumour, 
particularly when done only in bi-Libyan Journal of Medicine, Volume 1, 2006
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opsies, where the exact depth of 
tumour inﬁltration into the bowel 
wall, LNN involvement, and the 
data on distant metastases can-
not be obtained. There is increas-
ing recent evidence, however, that 
light microscopic examination of 
the primary tumour by quantita-
tive measurements could provide 
useful prognostic information 
(62).
Currently, computer-assisted im-
age analysis (nuclear morphom-
etry) provides a new powerful 
tool for high-precision measure-
ment of several variables char-
acterising the size and shape of 
cancer cell nuclei in conventional 
tissue sections (63, 64). Several 
of these nuclear proﬁles seem to 
be useful prognostic predictors 
in various human malignancies 
(65, 66). Until now, however, few 
studies have used morphometric 
measurements to determine the 
nuclear size and shape proﬁles in 
normal and neoplastic colorectal 
tissues (67). Not unexpectedly, 
the nuclear size is usually larger 
and its shape is more often irreg-
ular in cancer cells (68, 69).
In 1982, Diamond and associates 
introduced nuclear morphometry 
to aid in prediction of prognosis 
among patients with prostate can-
cer (70, 71). He and his colleagues 
observed that nuclear roundness 
was very useful in separating long 
survivors among stage B patients 
from those who develop metas-
tasis. They observed no overlap 
in nuclear roundness between 
the two groups. Since then, many 
histological studies (72-76) have 
used nuclear morphometry to 
predict prognosis in patients with 
prostate cancer. Eichenberger 
and associates (73) calculated 12 
shape descriptors including nu-
clear roundness, ellipticity factors, 
and concavity factors. They used 
discriminate analysis to select the 
major morphometric parameters 
which best distinguished patients 
with good or poor prognosis. El-
liptical shape measurement was 
found to be the best in this re-
spect.
To critically evaluate the useful-
ness of nuclear morphometry for 
prediction of prognosis, Partin 
et al (75) developed a morpho-
metric evaluation system called 
Hopkin’s Morphometry System, 
and produced and compared 15 
different shape descriptors in 
stage A2 prostate cancer. These 
were analyzed by 17 different 
statistical tests. The best sepa-
ration was provided by the lower 
quartile analysis of the ellipticity 
shape descriptor (p<0.01). These 
studies revealed that the elliptical     www.ljm.org.ly   
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shape of the nuclei is very impor-
tant as a prognostic factor.
The results of the study by Mar-
tinez-Jabaloyas et al (77) re-
vealed that mean nuclear area 
and other factors proved to have 
a prognostic value in the univari-
ate analysis and concluded (78) 
that nuclear morphometry in the 
primitive tumor provides inde-
pendent prognostic information in 
survival analysis for patients with 
metastatic prostate cancer. The 
combined evaluation of high nu-
clear morphology, ploidy, and cell 
survival parameters such as Bcl-
2 expression might better iden-
tify patients with poor prognosis 
among early stage prostate car-
cinomas diagnosed by FNA biop-
sies (79).
Besides the prognostic and pre-
dictive power of morphometry, 
Buhmeida et al (80) revealed 
that the nuclear size features 
are useful in distinguishing be-
tween different atypia groups of 
the prostate gland in ﬁne needle 
aspiration biopsies, particularly if 
the sample-associated means of 
the size features (area, diameter, 
perimeter, short and long axes) 
are used for the interpretation of 
data. The study suggested if the 
upper range limit of sample-as-
sociated mean areas of nuclei is 
below 27μm2, it is most probable 
that we are dealing with benign 
cells. If the upper range limit is 
above 39μm2, it is possible that 
there are malignant cells in the 
sample. However, values above 
52μm2 represent malignant sam-
ples with certainty. Further stud-
ies will be necessary for associ-
ating nuclear size features with 
Gleason grades.
IN SUMMARY
Cytometric analysis of cellular 
DNA content can be performed 
rapidly and with relative ease 
and there is accumulating evi-
dence that it provides an objec-
tive assessment of the inherent 
malignant potential in a number 
of human cancers. It seems like-
ly that determination of tumors’ 
ploidy will add signiﬁcantly to the 
clinical and pathological assess-
ment. Unfortunately DNA ploidy 
measurements from biopsies are 
rare in clinical practice, in spite of 
the extensive literature that sup-
ports their use (81). This, in fact, 
needs to be emphasized in more 
educational courses to those who 
are dealing with cancer. Unfor-
tunately, there is a gap between 
the scientiﬁc researchers and cli-
nicians who are treating cancer 
patients. Our target is to reduce 
this gap and enhance people to Libyan Journal of Medicine, Volume 1, 2006
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learn more about the importance 
of implementing such tools in rou-
tine clinical practice to help them 
in taking the right treatment deci-
sions.
Compound prognostic factors 
based on the gene expression 
proﬁles (tested by DNA arrays) 
are promising and will acceler-
ate the discovery of new predic-
tive and prognostic molecules, 
but clinically relevant data up to 
this moment are still lacking (82). 
Multivariate analyses of prog-
nostic factors are enough, and 
multivariate models for predic-
tion of compound prognosticators 
or predictors have not been well 
tested in clinical practice.
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